The American Psychiatric Association Publishing Textbook of Psychopharmacology, Sixth Edition

More than 160 authors—including more than 75 new contributors—lent their expertise to this sixth edition of The American Psychiatric Association Publishing Textbook of Psychopharmacology. Featuring 12 all-new chapters and fully aligned with the revised DSM-5-TR classification, this two-volume text offers an unrivaled, in-depth look at the rapidly evolving field of neuropsychopharmacology.

The opening chapters provide a whirlwind tour of the multiple disciplines that undergird the chapters to come, with topics extending from the principles of molecular biology and genomics to the rudiments of neuroimaging and personalized medicine in psychiatry. The main body of the Textbook features an examination of the medication classes that form the basis of psychopharmacological treatment. For each drug within a class, data are reviewed on history and discovery, preclinical and clinical pharmacology, pharmacokinetic parameters, mechanism of action, indications and efficacy, side effects and toxicology, and drug-drug interactions. The Textbook's second volume focuses on psychopharmacological approaches to treatment of patients with major psychiatric disorders (e.g., mood and anxiety disorders, schizophrenia, substance use disorders) as well as patients in specific populations (e.g., adults with ADHD, pediatric patients). For each specific condition, patient population, or setting, chapters provide guidance on topics such as medication selection, combination and maintenance dosing regimens, side-effect monitoring and management, and optimization of treatment response. Closing this volume is an Appendix of Psychiatric Medications with key information on each of the agents covered in the Textbook, presented in a convenient tabular format.

Noteworthy additions to this textbook include chapters addressing the following topics:

• The potential roles of personalized medicine in psychiatry and of artificial intelligence and machine learning in psychopharmacology• New medications with novel pharmacological mechanisms, including the neurosteroid antidepressant brexanolone and the atypical antipsychotic pimavanserin• Use of investigational agents, such as psychedelics, in psychiatric treatment• Treatment of alcohol use disorder, PTSD, OCD, and autism spectrum disorder• Treatment of ADHD in adults• Treatment of women in all life phases, including during pregnancy and the postpartum period• Treatment of individuals with intellectual developmental disorder

With a level of detail not found in any other source, this new edition of The American Psychiatric Association Publishing Textbook of Psychopharmacology illuminates the path to effective evidence-based practice of psychopharmacology for novice and seasoned clinicians alike.

Table of Contents:

PART I Principles of Pharmacology

1 Basic Principles of Molecular Biology and Genomics

2 Neurotransmitters, Receptors, and Transporters

3 Genetics and Epigenetics

4 Psychoneuroendocrinology

5 Brain–Immune System Interactions

6 Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics

Appendix: Pharmacokinetic Parameters of Specific Medications

7 Neuroimaging and Psychiatry

8 Personalized Medicine in Psychiatry

9 Machine Learning in Psychopharmacology

PART II Classes of Psychiatric Treatments

Antidepressants and Anxiolytics

10 Monoamine Oxidase Inhibitors

11 Tricyclic and Tetracyclic Drugs

12 Fluoxetine and Fluvoxamine

13 Sertraline and Paroxetine

14 Citalopram and Escitalopram

15 Trazodone and Nefazodone

16 Vortioxetine

17 Mirtazapine

18 Bupropion

19 Venlafaxine and Desvenlafaxine

20 Duloxetine, Milnacipran, and Levomilnacipran

21 Ketamine and Esketamine

22 Benzodiazepines

23 Buspirone

24 Brexanolone and Other Neurosteroids

Antipsychotics

25 Classic Antipsychotic Medications

26 Clozapine

27 Olanzapine

28 Quetiapine

29 Risperidone and Paliperidone

30 Aripiprazole and Brexpiprazole

31 Ziprasidone and Asenapine

32 Iloperidone

33 Lurasidone

34 Cariprazine

35 Pimavanserin

36 Management of Psychiatric Medication–Induced Movement Disorders

Drugs for Treatment of Bipolar Disorder

37 Lithium

38 Valproate

39 Carbamazepine, Oxcarbazepine, and Eslicarbazepine

40 Gabapentin and Pregabalin

41 Lamotrigine

42 Topiramate

Other Agents

43 Agents for Neurocognitive Disorders

44 Sedative-Hypnotics

45 Psychostimulants and Wakefulness-Promoting Agents

46 Electroconvulsive Therapy and Other Neuromodulation Therapies

47 Psychedelic Drugs as Treatments in Psychiatry

Index

Figure Color Plates

Volume II Contents

Contributors

Introduction

PART III Psychopharmacological Treatment

48 Treatment of Depression

49 Treatment of Bipolar Disorder

50 Treatment of Anxiety Disorders

51 Treatment of Posttraumatic Stress Disorder

52 Treatment of Obsessive-Compulsive Disorder …

53 Treatment of Schizophrenia

54 Treatment of Substance Use Disorders

55 Treatment of Alcohol Use Disorder

56 Treatment of Personality Disorders

57 Treatment of Eating Disorders

58 Treatment of Insomnia

Appendix: Properties of Agents Commonly Used to Treat Insomnia

59 Treatment of Chronic Pain

60 Treatment of Child and Adolescent Disorders

Appendix: Psychotropic Medications Commonly Prescribed for Children and Adolescents

61 Treatment During Late Life

62 Treatment of Women Excluding Pregnancy and Postpartum

63 Psychopharmacology During Pregnancy and Lactation

64 Treatment of Attention-Deficit/Hyperactivity Disorder in Adults

65 Treatment of Individuals With Intellectual Developmental Disorder

66 Treatment of Autism Spectrum Disorder

Appendix: Outcome Measures for Assessment of Core Symptom Domains in Autism Spectrum Disorder

67 Treatment of Psychiatric Emergencies

Appendix of Psychiatric Medications

Index